Bristol-Myers Squibb Co (BMY) Holdings Trimmed by Comerica Bank
Comerica Bank lessened its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.8% during the third quarter, Holdings Channel reports. The institutional investor owned 619,419 shares of the biopharmaceutical company’s stock after selling 5,127 shares during the quarter. Comerica Bank’s holdings in Bristol-Myers Squibb were worth $37,685,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also made changes to their positions in BMY. Tradewinds Capital Management LLC grew its position in shares of Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the last quarter. Atlantic Trust LLC acquired a new position in shares of Bristol-Myers Squibb in the second quarter valued at approximately $111,000. Massey Quick Simon & CO. LLC grew its position in shares of Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. grew its position in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the last quarter. Finally, BDO Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the second quarter valued at approximately $123,000. 69.74% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $62.81 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. The stock has a market capitalization of $102,800.00, a P/E ratio of 24.73, a P/E/G ratio of 2.30 and a beta of 1.18. Bristol-Myers Squibb Co has a 12 month low of $46.01 and a 12 month high of $66.10.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.99%.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were acquired at an average price of $62.30 per share, with a total value of $249,200.00. Following the completion of the purchase, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by corporate insiders.
BMY has been the topic of several research reports. UBS Group reaffirmed a “buy” rating and issued a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Vetr raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price on the stock in a research report on Monday, October 9th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Thursday, October 12th. Finally, Citigroup upped their target price on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $65.11.
ILLEGAL ACTIVITY NOTICE: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2018/01/16/bristol-myers-squibb-co-bmy-holdings-trimmed-by-comerica-bank.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Stock Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related stocks with our FREE daily email newsletter.